血清血管内皮生长因子及白介素8在2型糖尿病视网膜病变患者中的水平及其临床意义

Serum VEGF and IL-8 expression in patients with type 2 diabetic retinopathy and its clinical significance

目的：探讨白介素‐8（IL‐8）能否作为 T2DM 视网膜病抗血管内皮生长因子（VEGF）治疗的联合治疗靶点。方法 T2DM患者112例，按有无并发症分为单纯 T2DM 组和糖尿病视网膜病变（DR）组。同时收集健康体检者36名为健康对照组（NC组）。放射免疫法（RIA ）测定受试者血清VEGF和IL‐8含量。结果 T2DM 组与 DR组 VEGF含量较 NC 组分别升高1.73倍[（5.26±3.54） vs （9.10±4.85）ng／ml ，P＜0.05）和4.53倍[（5.26±3.54） vs （23.86±16.16）ng／ml ，P＜0.05）]，DR组较T2DM组升高2.62倍[（9.10±4.85） vs （23.86±16.16）ng／ml ，P＜0.05）]；T2DM组与DR组IL‐8含量与NC组比较分别升高7.42倍[（25.69±2.47） vs （190.50±27.17）ng／ml ，P＜0.05）]和69.72倍[（25.69±2.47） vs （1791.00±297.30）ng／ml ，P＜0.05）]，DR组较 T2DM 组升高9.4倍[（190.50±27.17） vs （1791.00±297.30）ng／ml ，P＜0.05）]。VEGF曲线下面积（AUC）为0.89，95％ CI为0.84～0.94（P＜0.001）；IL‐8的 AUC为0.82，95％ CI为0.75～0.89（P＜0.001）。在 NC组中，血清IL‐8与VEGF含量无相关性（r＝0.1232，P＞0.05），但在 T2DM 组和DR组中，IL‐8与 VEGF呈正相关（r＝0.6128、0.8671，P＜0.05）。结论 IL‐8可作为DR抗VEGF治疗的联合治疗靶点和危险评估因素。

Objective To investigate whether IL‐8 could be a potential therapy target of type 2 diabetic retinopathy combining with anti‐vascular endothelial growth factor VEGF treatment.Methods A total of 112 patients with type 2 diabetes （T2DM ） were enrolled in this study and divided into two groups ：T2DM group and diabetic retinopathy group （DR group ） according to the incidence of complication. 36 healthy subjects were also enrolled in this study as normal glucose tolerance group （NC group）. Serum VEGF and IL‐8 expression were determined using radioimmunoassay. Results Serum VEGF increased 1.73 fold [（5.26 ± 3.54 ） vs （9.10 ± 4.85 ）ng/ml ,P〈0.05 ）] and 4.53 fold [（5.26 ± 3.54） vs （23.86 ± 16.16）ng/ml ,P〈 0.05）] in T2DM and DR group than in NC group ,serum VEGF increased 2.62 fold [（9.10 ± 4.85） vs （23.86 ± 16.16）ng/ml ,P〈 0.05）] in DR group than in T2DM group. Serum IL‐8 increased 7.42 fold [（25.69 ± 2.47） vs （190.50 ± 27.17）ng/ml ,P〈0.05）] and 69.72 fold [（25.69 ± 2.47） vs （1791.00 ± 297.30）ng/ml ,P〈0.05）] in T2DM and DR group than in NC group.Serum IL‐8 increased 9.4 fold [（190.50 ± 27.17 ） vs （1791.00 ± 297.30 ）ng/ml ,P〈0.05 ）] in DR groupthan in T2DM group. AUC of VEGF was 0.89 ,95% CI 0.84~0.94 ,P〈0.001. AUC of IL‐8 was 0.82 , 95% CI 0.75~0.89 ,P〈0.001. Serum IL‐8 was positively related to VEGF in T 2DM group （r=0.6128 , P〈0.05） and DR group（r=0.8671 ,P〈0.05） ,but not in NC group （r=0.1232 ,P〉0.05）. Conclusion IL‐8 could be a potential therapy target combined with anti‐VEGF and be a prognosis monitoring factor for diabetic retinopathy.